JUAN AREVALO-SERRANO

Dr. JUAN AREVALO-SERRANO

Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jorge Monserrat SanzJorge Monserrat Sanz
Jorge Monserrat Sanz
AGAna Gómez-Lahoz
Ana Gómez-Lahoz
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
JSJOSÉ SANZ-MORENO
JOSÉ SANZ-MORENO
BMBenjamin Muñoz
Benjamin Muñoz
OGon behalf of the COVID-19 HUPA Group
on behalf of the COVID-19 HUPA Group
SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system—IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII—for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFβ, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the disease.

31 October 2015 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
YGYago González-Lama
Yago González-Lama
CSCristina Suárez
Cristina Suárez
IGIrene González-Partida
Irene González-Partida
MCMarta Calvo
Marta Calvo
VMVirginia Matallana
Virginia Matallana
LALuis Abreu
Luis Abreu
Introduction: Early stages of Crohn’s disease [CD] are predominantly inflammatory and early treatment could be useful to change the natural history of CD. We aimed to evaluate the impact of early treatment in our cohort of CD patients. Methods: We retrospectively reviewed clinical records of all CD patients at our centre who have received immunomodulators. Time from diagnosis to first CD-related major abdominal surgery or end of follow-up was considered. Dates of diagnosis, of starting immunomodulators (thiopurines / anti-tumour necrosis factor [TNF]), and of the first CD-related surgery when appropriate were collected. Results: Of 422 patients who received thiopurines, 189 operated patients started thiopurines after a median of 117 months (interquartile range [IQR] 44–196) since diagnosis; non-operated patients, after a median of 30 months [IQR 6–128], p < 0,005. Odds ratio [OR] for surgery was 1.006 (95% confidence interval [CI]1.004–1008) for each month of delay in starting thiopurines. Among 272 patients who received anti-TNFs, 137 operated patients started anti-TNFs after a median of 166 months [IQR 90–233] since diagnosis; non-operated patients after a median of 59 months [IQR 14–162]; p < 0,005. OR for surgery was 1.008 [95% CI 1.005–1.010] for each month of delay in starting anti-TNFs. Among 467 patients who received thiopurines and/or anti-TNF, 210 operated patients started any immunomodulator after a median of 120 months [IQR 48–197] since diagnosis and non-operated patients after a median of 30 months [IQR 6–126], p < 0,005. OR for surgery was 1.008 [95% CI 1.005–1.010] for each month of delay in starting immunomodulators. Conclusions: In our experience, time between diagnosis and thiopurine or anti-TNF initiation was associated with the risk of major abdominal surgery in Crohn’s disease.

15 October 2024 in BJPsych Open
Verified
Journal Article
Open access
PDF file
SRSancho Rodriguez-Villar
Sancho Rodriguez-Villar
EOElijah Oluwafemi Okegbola
Elijah Oluwafemi Okegbola
JAJUAN AREVALO-SERRANO
JUAN AREVALO-SERRANO
YDYasmine Duval
Yasmine Duval
AMAnnie Mathew
Annie Mathew
HPHolly Prigerson
Holly Prigerson
Background: The grief of relatives of patients who died of COVID-19 in an intensive care unit (ICU) has exacted an enormous toll worldwide. Aims: To determine the prevalence of probable prolonged grief disorder (PGD) at 12 months post-loss and beyond. We also sought to examine circumstances of the death during the COVID-19 pandemic that might pose a heightened risk of PGD, and the associations between probable PGD diagnosis, quality of life and social disconnection. Method: We conducted an observational, cross-sectional multicentre study of the next of kin of those who died of COVID-19 between March 2020 and December 2021. Participants were recruited from ICUs in South-East London. The Prolonged Grief Disorder Scale (PG-13-R), Quality-of-Life Scale (QOLS) and Oxford Grief-Social Disconnection Scale (OG-SD) were used. Results: A total of 73 relatives were recruited and assessed, all of them over a year after their loss. Twenty-five (34.2%; 95% CI 23.1–45.4%) relatives of patients who died in the ICU met the criteria for PGD. Those who met the criteria had significantly worse quality of life (QOLS score mean difference 26; 95% CI 17–34; P < 0.001) and endorsed greater social disconnection (OG-SD score means difference 41; 95% CI 27–54; P < 0.001). Conclusions: The findings suggest that rates of PGD are elevated among relatives of patients who died of COVID-19 in the ICU. This, coupled with worse quality of life and greater social disconnection experienced by those meeting the criteria, suggests the need to attend to the social deprivations and social dysfunctions of this population group.

12 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Jorge Monserrat SanzJorge Monserrat Sanz
Jorge Monserrat Sanz
AAAngel Asúnsolo
Angel Asúnsolo
AGAna Gómez-Lahoz
Ana Gómez-Lahoz
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
JGJose Maria Gasalla
Jose Maria Gasalla
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
Objective: To describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19. Design: An observational, analytical, retrospective cohort study with longitudinal follow-up. Setting: Hospital Universitario Príncipe de Asturias (HUPA). Participants: 287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020. Main outcome measures: Profiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (n = 19), innate inflammatory IR-related cytokines (n = 27), and growth factors (n = 16). Results: A statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF. Conclusions: When severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient’s inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.

23 September 2010 in Acta Ophthalmologica
Verified
Journal Article
Closed access
MCM Castejon
M Castejon
GBG Bolivar
G Bolivar
EAE Arranz‐Marquez
E Arranz‐Marquez
JAJUAN AREVALO-SERRANO
JUAN AREVALO-SERRANO
MTMa Teus
Ma Teus

26 November 2024 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
JAJosé Mª Barbero Allende
José Mª Barbero Allende
IUIván Ureña
Iván Ureña
LCLeticia Cañivano
Leticia Cañivano
SGSara García
Sara García
CPCristina Paz
Cristina Paz
JAJUAN AREVALO-SERRANO
JUAN AREVALO-SERRANO
Introduction. One of the main problems with Clostridioides difficile infection (CDI) is its tendency to recur. The objective of the study is to analyze which factors in the clinical management of CDI favor recurrence. Material and methods. This is a retrospective study conducted at the Hospital Universitario Príncipe de Asturias on cases of CDI between January 2021 and June 2023. Demographic variables, comorbidities, risk factors for recurrence, and treatments used for CDI were recorded. Non-optimal clinical management was defined as: not discontinuing treatment with proton pump inhibitors (PPIs) if the patient was on them, not discontinuing concomitant antibiotic treatments if the patient was on these, the use of metronidazole monotherapy in any case, or the use of standard-dose vancomycin if there were risk factors for recurrence. Results. A total of 327 cases were found in 256 patients. 69 patients died within 8 weeks after the episode (26.9%). Among the remaining 258 episodes, there were 68 recurrences (26.3%). Of these 68 recurrences, 63 cases received nonoptimal treatment (93.2%), compared to 112/190 (58.9%) among those who did not recur. In the multivariate analysis adjusted for confounding factors, patients who received optimal treatment had an 89% lower risk of recurrence compared to those who did not receive it (OR 0.1; p < 0.001). Conclusions. Reducing the use of PPIs and antibiotics and prioritizing more effective treatments against CDI could improve the recurrence rates of this infection.